International Journal of Hematology

DOI: 10.1007/s12185-017-2295-0 Pages: 355-364

Treatment-free remission in patients with chronic myeloid leukemia

1. Hôpital Saint-Louis, Service d’hématologie Adulte, Unité INSERM, UMR-1160 and France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)

2. Hôpital Saint-Louis, Laboratoire Central d’Hématologie, EA3518 Université Paris 7 and France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)

Correspondence to:
Delphine Rea
Tel: +33142499649



Clinical trials have formally demonstrated that in chronic myeloid leukemia (CML), patients treated with tyrosine kinase inhibitors (TKI) who achieved and maintained deep molecular responses could discontinue their treatment after several years without facing overt signs of disease relapse in approximately 50% of the cases. In patients with a molecular relapse, prompt re-introduction of TKI therapy was able to rapidly restore deep molecular responses. The concept of a lifelong therapy with TKI has thus been challenged and treatment-free remission (TFR) strategies will soon integrate clinical practice, providing that safe recommendations will be established. In this article, we give an update on TKI discontinuation studies in CML and we also provide an overview of upcoming TFR clinical and biological challenges.

This article is freely available, click here to access the full text/PDF

Share the Knowledge